RenovaCare (PK) Stock Price

0.00 (0.0%)
Volume 11
Bid Price 0.0552
Ask Price 0.14
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
RenovaCare Inc (PK) RCAR OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.10 13:30:28
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
2 11 - 0.055 - 2.91
Last Trade Time Type Quantity Stock Price Currency
15:20:32 1 $ 0.0976 USD


Draw Mode:

RenovaCare Inc (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 8.74M 87.35M 26.06M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
3.19k $ - - - -

more financials information »

RenovaCare (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RCAR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.070.106040.0550.063127612,6460.0342.86%
1 Month0.220.250.0550.11332119,877-0.12-54.55%
3 Months0.300.35960.0550.183431412,983-0.20-66.67%
6 Months0.930.970.0550.36031816,864-0.83-89.25%
1 Year2.802.910.0550.879243714,644-2.70-96.43%
3 Years1.1254.500.0552.0918,116-1.03-91.11%
5 Years4.0412.820.0554.0527,128-3.94-97.52%

RenovaCare (PK) Description

RenovaCare, Inc. is a development-stage biotechnology and medical device company focusing on the research, development and commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. The Company does not have any commercialized products. We are currently developing and testing the CellMist System which is a cell isolation procedure that enzymatically renders stem cells from the patients own skin or other tissues. The resulting stem cell suspension is administered topically with our SkinGun spray device as a cell therapy onto wounds, including burns, to facilitate healing. On May 6, 2021 the Food and Drug Administration gave full-approval of the Company's Investigational Device Exemption (IDE) application to proceed with initial clinical testing of the CellMist System and SkinGun spray device in adult burn patients. The clinical trial protocol is an open-label, single-arm clinical study that is enrolling 14 adult human burn subjects with partial-thickness, second-degree deep thermal burn wounds covering between 10% and 30% total body surface area. The Company may engage up to four (4) U.S. burn centers to conduct the clinical study. Currently, the clinical trial is activated, enrolling and treating patients. The CELLMIST 1 clinical study is expected to reach completion in late 2022.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.